Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2–negative advanced breast cancer from the United States, Europe, and Israel

Fig. 2

IPWRA Analysis for EQ-5D Health Utility. Mean EQ-5D Summary Index. EQ-5D, EuroQoL-5 Dimension; IPWRA, inverse-probability–weighted regression adjustment; PARPi, poly (ADP-ribose) polymerase inhibitors. Bold P values represent those that are statistically significant (p < 0.05). *Includes platinum- and non–platinum-based regimens. Error bars represent standard error

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us